Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02206048 · ClinicalTrials.gov registry record · NA
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix
A NA study of Cervix Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02206048 is a NA study of Cervix Carcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02206048, a NA study of Cervix Carcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if it is possible to get high-resolution microendoscopy (HRME) images of AIS tissue and/or tissue from microinvasive carcinoma right before a biopsy of the cervix. Researchers also want to learn if HRME images can show the difference between cancerous tissue and normal cervical tissue.
Conditions Studied
Interventions
- DRUG Proflavine
- PROCEDURE High-Resolution Microendoscopy (HRME) Imaging
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-10-02 |
| Est. Completion | 2021-04-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02206048
The ClinicalTrials.gov registry entry for NCT02206048 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cervix Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Proflavine is the first listed.
NCT02206048 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02206048 about?
NCT02206048 is a clinical study titled "Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix". The goal of this clinical research study is to learn if it is possible to get high-resolution microendoscopy (HRME) images of AIS tissue and/or tissue from microinvasive carcinoma right before a biopsy of the cervix. Researchers also want to learn if HRME images can show the difference between cance...
What is the current status of trial NCT02206048?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2015-10-02. Estimated completion is 2021-04-21.
What conditions does trial NCT02206048 study?
This clinical trial studies the following conditions: Cervix Carcinoma.
What interventions are being tested in trial NCT02206048?
The interventions under investigation include: Proflavine (DRUG), High-Resolution Microendoscopy (HRME) Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT02206048?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02206048 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.